Summary
Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:
Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
Specialised intelligence on OTCs, generics, biologics and biosimilars.
Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.
Description
THE PHARMACEUTICAL MARKET: POLAND - REVIEW
Poland has the second largest economy in Central & Eastern Europe, although in per capita terms it is around average. Poland was the only EU country that did not see its economy contract in 2009 and 2010 as a result of the economic crises. This was due to a fairly low dependency on loans, high consumer spending and the fact that exports account for only 30% of GDP. Poland is also the largest beneficiary of EU funds among the 27 member states, receiving around 20% of the EU's total financial support under the cohesion policy. The large population of 38.2 million keeps the demand for pharmaceuticals high. However, the overall population size is slowly decreasing whilst the population aged 65 years and over is rising, placing increased pressure on the health system.
In May 2011, President Komorowski signed a controversial Drug Reimbursement Act into law, which is designed to curb the growth of drug reimbursement expenditure. The measures in the Act, which are to take effect from January 2012, include limiting drug reimbursement expenditure to 17% of total public healthcare spending, forcing pharmaceutical companies to cover half of any drug reimbursement overspending, applying fixed retail prices to reimbursed medicines, introducing fixed margins for wholesalers and requiring certain physicians and wholesalers to sign contracts with the NFZ, agreeing to prescribe and sell medicines at the official, fixed price. There are concerns that the elderly and those on low incomes will not be able to afford the new official prices and the Office of Competition and Consumer Protection has stated that fixed prices and margins on reimbursed drugs contravene free market principles.
In 2011, the Polish market for pharmaceuticals is twice that of the Czech Republic; in per capita terms, the market is similar to Latvia. Imports supply around 63% of the market in value terms. The Polish pharmaceutical market is predicted to expand at a relatively strong CAGR over the next few years, driven by a relatively strong economy, import growth and the ageing population. The demand is currently for modern, innovative drugs, which are seldom developed by local manufacturers as most domestic producers do not have the resources to fund research into new molecules. Until local investments in R&D grow, overseas manufacturers have the opportunity to cover the areas that are currently overlooked.
ENHANCED STRATEGIC INTELLIGENCE
Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:
Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
Specialised intelligence on OTCs, generics, biologics and biosimilars.
Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.
HEALTHCARE STATISTICS
A comprehensive tabula review, comprising demographics, epidemiology, health expenditure, hospital and primary care infrastructure & services and healthcare personnel, is additionally included.
The Pharmaceutical Market: Poland published by Espicom Business Intelligence in January 31, 2013. This report consists of 102 Pages and the price starts from US $ 1295.
The contents of this page may be different from the latest version. Please contact us for details.
